Research Article

Five-Year Assessment of Time of Sputum Smears Conversion and Outcome and Risk Factors of Tuberculosis Patients in Central Iran

Table 2

Impact of comorbidities and demographic, microbiological, and therapeutic variables on sputum smear conversion at the end of the intensive phase ().

Characteristic Sputum conversion status value
Conversion number (%)Nonconversion number (%)

Sex Male83 (83.8)16 (16.2)0.925
Female75 (83.3)15 (16.7)

Age≤5060 (80)15 (20)0.279
>5098 (86)16 (14)

NationalityIranian84 (85)15 (15)0.626
Non-Iranian74 (82.2)16 (17.8)

Initial sputum grading≤2+122 (88.4)16 (11.6)0.003
3+ 35 (70) 15 (30)

Accompanying diseaseDM14 (70)6 (30)0.033
Otherwise healthy (No comorbidity) 136 (87.8) 19 (12.2)

Treatment regimenHRZE139 (83.7)27 (16.3)0.625
HRZES* 13 (86.7) 2 (13.3)
HRE 4 (66.7) 2 (33.3)
HZE 2 (100) 0 (0)

Treatment categoryCAT I144 (83.2)29 (16.8)0.660
CAT II 14 (87.5) 2 (12.5)

HRZES*: isoniazide, rifampicin, pyrazinamide, ethambutol, and streptomycin.